Patents by Inventor Liusheng Zhu

Liusheng Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200062780
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 13, 2019
    Publication date: February 27, 2020
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Publication number: 20200055892
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: September 5, 2019
    Publication date: February 20, 2020
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Patent number: 10472387
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 12, 2019
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina
  • Publication number: 20190218246
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: March 26, 2019
    Publication date: July 18, 2019
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Publication number: 20190023720
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 24, 2019
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S, LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Publication number: 20190016736
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 17, 2019
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Patent number: 10100063
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: October 16, 2018
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li
  • Publication number: 20170088560
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: December 12, 2016
    Publication date: March 30, 2017
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Publication number: 20160068545
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 28, 2015
    Publication date: March 10, 2016
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc VIMOLRATANA, Xianghong Wang, Ming Yu, Manuel ZANCANELLA, Liusheng Zhu, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Patent number: 8748462
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I?A or I?B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: June 10, 2014
    Assignee: Amgen Inc.
    Inventors: Sean P. Brown, Paul Dransfield, Xiaohui Du, Zice Fu, Jonathan Houze, XianYun Jiao, Sujen Lai, An-Rong Li, Jiwen Liu, Zhihua Ma, Julio C. Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang, Ming Yu, Liusheng Zhu
  • Patent number: 8450522
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: May 28, 2013
    Assignee: Amgen Inc.
    Inventors: Sean P. Brown, Paul J. Dransfield, Jonathan Houze, Todd J. Kohn, Jiwen Liu, Julio Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Ming Yu, Liusheng Zhu
  • Patent number: 8030354
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 4, 2011
    Assignee: Amgen Inc.
    Inventors: Sean P. Brown, Qiong Cao, Paul John Dransfield, Xiaohui Du, Zice Fu, Jonathan Houze, Xian Yun Jiao, Yong-Jae Kim, Todd J. Kohn, SuJen Lai, An-Rong Li, Daniel Lin, Jiwen Liu, Jian Luo, Julio C. Medina, Jeffrey D. Reagan, Vatee Pattaropong, Margrit Schwarz, Wang Shen, Yongli Su, Gayathri Swaminath, Marc Vimolratana, Yingcai Wang, Yumei Xiong, Li Yang, Ming Yu, Jie Zhang, Liusheng Zhu
  • Publication number: 20110190330
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I?A or I?B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: October 13, 2009
    Publication date: August 4, 2011
    Applicant: AMGEN INC.
    Inventors: Sean P. Brown, Paul Dransfield, Xiaohui Du, Zice Fu, Jonathan Houze, XianYun Jiao, Sujen Lai, An-Rong Li, Jiwen Liu, Zhihua Ma, Julio C. Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang, Ming Yu, Liusheng Zhu
  • Publication number: 20100298367
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: March 4, 2009
    Publication date: November 25, 2010
    Inventors: Sean P. Brown, Paul J. Dransfield, Jonathan Houze, Todd J. Kohn, Jiwen Liu, Julio Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Ming Yu, Liusheng Zhu
  • Patent number: 7816367
    Abstract: The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q-L1-P-L2-M-X-L3-A wherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: October 19, 2010
    Assignee: Amgen Inc.
    Inventors: Michelle Akerman, Jonathan Houze, Daniel C. H. Lin, Jiwen Liu, Jian Luo, Julio C. Medina, Wei Qiu, Jeffrey D. Reagan, Rajiv Sharma, Stephen J. Shuttleworth, Ying Sun, Jian Zhang, Liusheng Zhu, Jinqian Liu, Zhihua Ma, Yingcai Wang, Michael J. Schmitt
  • Patent number: 7649110
    Abstract: The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q—L1—P—L2—M—X—L3—A wherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: January 19, 2010
    Assignee: Amgen Inc.
    Inventors: Michelle Akerman, Jonathan Houze, Daniel C. H. Lin, Jinqian Liu, Jiwen Liu, Jian Luo, Zhihua Ma, Julio C. Medina, Wei Qiu, Jeffrey D. Reagan, Rajiv Sharma, Michael J. Schmitt, Stephen J. Shuttleworth, Ying Sun, Yingcai Wang, Jian Zhang, Liusheng Zhu
  • Publication number: 20090275598
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L1, L2, M, X, L3, and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: July 10, 2009
    Publication date: November 5, 2009
    Applicant: Amgen Inc.
    Inventors: Michelle Akerman, Sean Brown, Jonathan B. Houze, Jinqian Liu, Jiwen Liu, Zhihua Ma, Julio C. Medina, Wei Qiu, Michael J. Schmitt, Rajiv Sharma, Yingcai Wang, Liusheng Zhu
  • Patent number: 7582803
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L1, L2, M, X, L3, and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: September 1, 2009
    Assignee: Amgen Inc.
    Inventors: Michelle Akerman, Sean Brown, Jonathan B. Houze, Jinqian Liu, Jiwen Liu, Zhihua Ma, Julio C. Medina, Wei Qiu, Michael J. Schmitt, Yingcai Wang, Liusheng Zhu, Rajiv Sharma
  • Publication number: 20090137561
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: October 3, 2008
    Publication date: May 28, 2009
    Applicant: Amgen Inc.
    Inventors: Sean P. Brown, Qiong Cao, Paul John Dransfield, Xiaohui Du, Jonathan Houze, Xian Yun Jiao, Yong-Jae Kim, Todd J. Kohn, SuJen Lai, An-Rong Li, Daniel Lin, Jian Luo, Julio C. Medina, Jeffrey D. Reagan, Vatee Pattaropong, Margrit Schwarz, Wang Shen, Yongli Su, Gayathri Swaminath, Marc Vimolratana, Xiang Wang, Yumei Xiong, Li Yang, Ming Yu, Jie Zhang, Liusheng Zhu
  • Patent number: 7465804
    Abstract: The present invention provides compounds useful, for example, for modulating insulin levels in a subject, having the general formula I: wherein Q is an optionally substituted phenyl; L is a bond or O; P is a benzene or an optionally substituted thiazole ring; and R1 has the values provided herein. The present invention also provides compositions, uses, and methods for use of the compounds, for instance, for treatment of type II diabetes.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: December 16, 2008
    Assignee: Amgen Inc.
    Inventors: Jonathan Houze, Jiwen Liu, Zhihua Ma, Julio C. Medina, Michael J. Schmitt, Rajiv Sharma, Ying Sun, Yingcai Wang, Liusheng Zhu